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Abstract Acne vulgaris, hirsutism, seborrhea and female pattern hair loss (FPHL) are common disorders of the
pilosebaceous unit (PSU). In somewomenwith hyperandrogenemia, an excess of androgens at the PSU can lead
to the development of these dermatologicalmanifestations. Thesemanifestations can causemanypsychiatric and
psychological implications, such as social fears and anxiety, and can adversely affect quality of life.
High androgen levels at the PSU as a possible underlying cause of acne vulgaris, hirsutism, seborrhea and
FPHL supports the rationale for using combined oral contraceptives for the management of these con-
ditions in women. The purpose of this review is to describe these dermatological manifestations of the
PSU and the management of these conditions through the use of the oral contraceptive ethinylestradiol/
chlormadinone acetate (EE/CMA).
EE/CMA 0.03/2mg is a combined monophasic contraceptive pill with anti-androgenic properties. It is
approved in Europe for contraception and has been investigated in phase III trials for the treatment of acne.
EE/CMA was better than placebo and similar to another low-dose oral contraceptive (ethinylestradiol/
levonorgestrel) in improving symptoms of acne in two phase III randomized controlled trials in patients with
mild to moderate papulopustular acne. In addition, in trials investigating the contraceptive efficacy of
EE/CMA, limited data suggest that there were also improvements in hirsutism, FPHL and seborrhea in
small subgroups of patients.
EE/CMA has a good safety profile. The most commonly reported adverse events are breast tenderness/
pain, headache/migraine and nausea.
Evidence in the literature indicates that the use of EE/CMA for the treatment of dermatological disorders
under the control of androgens may be a valid treatment option. Further investigation is warranted.
1. Introduction
Acne vulgaris, hirsutism, seborrhea and female pattern hair
loss (FPHL) are common disorders of the pilosebaceous unit
(PSU), which consists of a sebaceous gland and a hair follicle.[1]
These disorders occur after the onset of puberty and are related
to the development of sebaceous glands and terminal hair fol-
licles.[1] This development process is influenced by various fac-
tors including androgens; androgens bind to androgen receptors
in the PSU and promote the proliferation and differentiation of
sebaceous glands and follicular hyperkeratinisation.[1] The
response of the PSU to androgens is dependent on their loca-
tion in the body.[2]
In women, testosterone formation occurs largely in the
skin.[2] Dehydroepiandrosterone, dehydroepiandrosterone
sulfate and androstenedione are secreted and then peripherally
converted to testosterone.[2] The biological activity of testos-
terone on the PSU is dependent on the conversion of testos-
terone to dihydrotestosterone, an androgen that has high
potency in the PSU.[1] This is catalyzed by the enzyme 5a-
reductase.[1] There are two isozymes of 5a-reductase (types 1
and 2), which are differentially expressed in various tissues
such as the sex organs and the skin.[2] In hair follicles and se-
baceous glands, a local excess and influence of dihydrotesto-
sterone can lead to the development of acne vulgaris, hirsutism,
seborrhea and FPHL.[1] This excess is the result of either a change
in the interaction of the androgen/androgen receptor complex
genome or as a result of elevated testosterone levels in the PSU.[1]
While there is growing evidence that androgens play a sig-
nificant role in the pathogenesis of acne vulgaris, hirsutism,
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seborrhea and FPHL, other factors such as genetic predis-
position are also involved in the development of these PSU
disorders.[2] Acne and hirsutism can develop in women with nor-
mal serum levels of testosterone, while some women with elevated
circulating androgen levels (hyperandrogenemia), may show no
symptoms of these PSUdisorders (cryptic hyperandrogenemia).[2]
Women of childbearing potential, in the peak of their hor-
monal youth, present to dermatologists in search of solutions
for these dermatological disorders of the PSU. Frequently,
women who present to their GP or dermatologist have normal
androgen levels; however, some of these women present with
authentic hyperandrogenemia. In this scenario, women may
benefit from concomitant therapy with oral contraceptives
with anti-androgen effects in combination with strong anti-
androgens or other medications.[3]
The purpose of this review is to describe the dermatological
manifestations of androgen-related disorders of the PSU in
women and the management of these conditions through the
use of the oral contraceptive ethinylestradiol/chlormadinone
acetate (EE/CMA).
2. Acne Vulgaris
Acne vulgaris is a chronic inflammatory dermatological
condition characterized by open and/or closed comedones and
inflammatory papules, pustules or nodules.[4,5] Factors leading
to acne formation include the abnormal desquamation of fol-
licular epithelial cells and an enhanced production of sebum.[1,5]
In addition, the proliferation of Propionibacterium acnes in the
PSU can also be a causative factor.[5]
In women with acne, not only is there frequent hyper-
sensitivity of the sebaceous glands to androgens but there is also
often a systemic excess of androgens.[5] These factors lead to the
abnormal cellular development and extra sebum in turn re-
sulting in the comedones, papules, pustules and nodules that
characterize acne.Women with conditions that cause androgen
excess, such as polycystic ovary disease, regularly show symp-
toms of acne.[6]
Acne is one of the most common skin disorders.[7] Acne
occurs commonly in adolescence; however, in a study examining
the prevalence of acne in adults aged 20–49 years, acne was
reported in 26.3–50.9% of women.[7] The prevalence of acne
decreases with age, with 50.9% of women aged 20–29 years re-
porting acne compared with 26.3% of women aged 40–49 years.[7]
Acne has many psychiatric and psychological implications and
can adversely affect quality of life.[8,9] Women with acne may
experience clinical depression, anxiety and social anxiety, and
often women are more embarrassed by their acne than men.[10]
3. Hirsutism
Hirsutism is defined as excessive androgen-dependent male
pattern hair growth in women.[2] An increased density of ter-
minal hairs is observed in hormonally sensitive areas such as the
upper lip, chin, midchest, upper and lower back, upper and
lower abdomen, arm, forearm, thigh and lower leg.[2]
The transformation of small, fine and unpigmented vellus
hair follicles to terminal hair follicles, which are longer, thicker
andmore pigmented, is stimulated by androgens.[1] Hirsutism is
correlated more with plasma levels of free testosterone than
levels of total testosterone.[1] Moderate to severe hirsutism
is caused by above-normal free plasma testosterone levels,
whereas mild hirsutism can occur even when plasma-free
testosterone levels are within the normal range. Indeed, half of
all women with hirsutism have normal plasma levels of free
testosterone.[1] One final factor that is often elevated in hirsute
women is the activity of 5a-reductase type 2 in hair follicles.[11]
Hirsutism is prevalent in 5–10% of reproductive women in the
general population, and can be associatedwith a negative effect on
awoman’s quality of life.[12] Common causes for hirsutism include
polycystic ovary syndrome, idiopathic hirsutism, Cushing’s syn-
drome, acromegaly, hyperprolactinemia, ovarian or adrenal
androgen-secreting tumors, non-classic adrenal hyperplasia and
some drugs.[12] Many women with hirsutism report an increase in
social fear and anxiety, and hirsutism can lead to psychological
distress with an increase in psychotic symptoms.[13]
4. Female Pattern Hair Loss
FPHL is the androgen-dependent thinning of hair that occurs
with advancing age but can begin as early as in the teens.[2] FPHL
is also referred to as androgenetic alopecia; however, androgenetic
alopecia is alopecia that is androgen-independent. FPHL is the
result of the transformation of terminal hair follicles to small, fine
and unpigmented vellus hair follicles in addition to a reduction of
PSUs on the scalp.[2] FPHL develops in a pattern that is distinct
from age-related thinning; in women it is demonstrated by a dif-
fuse thinning of hair growth in the frontal and sagittal scalp.[1]
FPHL occurs due to a shortened anagen phase of scalp hair
growth: androgens shorten this phase and an increased dihy-
drotestosterone action on scalp hair follicles can reduce the
growth and production of hair.[1] Hair loss in certain regions of
the scalp with advancing age can also be attributed to an altered
androgen/estrogen ratio.
Approximately 10% of premenopausal women have FPHL.
The incidence increases with age and 25–32% of women aged
65 years or older experience FPHL.[14] Women with FPHL
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experience a diminished body image satisfaction and lowered
self-esteem.[15,16]
5. Seborrhea
Seborrhea or seborrheic dermatitis is a common chronic
inflammatory skin disorder that affects the scalp, face and
sebum gland-rich areas.[17,18] Seborrhea typically presents with
erythematous plaques or patches, but can vary from mild
dandruff of the scalp to thick, yellow and greasy areas on the
face, head and trunk.[17,18] Seborrhea can be caused by many
factors including increased androgen levels, nutritional deficits,
neurogenic factors and fungal infections.[19]
There is evidence that human sebocytes respond to androgen
stimulation, as reviewed by Zouboulis et al.[20] An increase in
free testosterone in women appears to increase sebum pro-
duction by sebocytes in turn causing seborrhea.
Seborrhea affects 3% of the general population.[17] Sebor-
rhea is most prevalent in adolescents, young adults and adults
over 50 years of age.[18] However, most patients (70%) experi-
ence mild symptoms.[18,19]
6. Rationale for the Use of Oral Contraceptives for the
Treatment of Pilosebaceous Unit Disorders
The use of oral hormonal treatments for acne vulgaris, hirsut-
ism, FPHL and seborrhea has a physiological rationale.[2]
Combined oral contraceptives contain an estrogen (such as ethi-
nylestradiol or mestranol) and a progestin (such as desogestrel,
drospirenone, levonorgestrel or chlormadinone).[21] Together they
reduce the effect of androgens by reducing ovarian and adrenal
androgen production and by blocking the action of androgens in
the PSU. The ethinylestradiol component inhibits luteinizing hor-
mone[22] and follicle-stimulating hormone (FSH) thus reducing
serumandrogen levels.[23] In addition, ethinylestradiol increases sex
hormone-binding globulin levels, which decrease circulating serum
testosterone levels.[23] The progestin component blocks the andro-
gen receptor in thePSU (i.e. is anti-androgenic).[23] Because of these
properties, estrogen-containing oral contraceptives are a recom-
mended treatment option in the management of acne vulgaris.[4]
EE/CMA is among the most commonly used combined oral
contraceptives, and has an anti-androgenic effect; a review of its
potential use for the improvement of dermatological manifes-
tations associated with hyperandrogenemia follows.
7. Ethinylestradiol/Chlormadinone Acetate
EE/CMA 0.03mg/2mg is a combined monophasic contra-
ceptive pill with anti-androgenic properties.[24-27] EE/CMA con-
tains the estrogen, ethinylestradiol and the progestin chlormadi-
none acetate. It is approved in Europe for contraception[28]
(Balianca, Belara) where it has also undergone testing in phase
III clinical trials for the treatment of acne;[24,29] the combina-
tion therapy is not approved for use in the USA.
Ethinylestradiol reduces serum FSH levels, preventing
ovarian follicular development and leading to a reduction in cir-
culating estradiol. Estradiol is essential for the pre-ovulatory re-
lease of luteinizing hormone, thus reducing circulating estradiol
levels and in turn preventing ovulation.[30] Chlormadinone acetate
synergistically inhibits follicular growth and maturation by
disrupting endogenous gonadotropin secretion.[31,32] In addi-
tion, chlormadinone acetate inhibits estrogen and progesterone
receptors, in turn inducing a thinning of the endometrium and a
reduction in the probability of embryo implantation.[33]
The efficacy of EE/CMA in contraception is well establish-
ed.[25,26,28,34,35] As described earlier, the ethinylestradiol com-
ponent reduces serum FSH levels and the chlormadinone
acetate component inhibits follicular growth and endogenous
gonadotropin secretion, which explains its potential to improve
skin disorders that are thought to be attributable to hyper-
androgenemia. To evaluate the literature concerning the rela-
tionship between EE/CMA and skin disorders a search was
conducted and studies used in this review were identified via the
MedLine and EMBASE databases using the terms: ethinyles-
tradiol AND chlormadinone AND acne OR seborrhea OR
hirsutism OR alopecia. All years of publication were included
dating back to 1966. Reference lists of identified publications
were also scanned for articles relevant to the topic and some
references known to the author were included. Only studies in
humans and English language articles were included.
7.1 Ethinylestradiol/Chlormadinone Acetate in Acne
EE/CMA treatment was associated with a clinical response
in significantly more patients than with placebo in a randomized
phase III trial in 377 patients with moderate papulopustular
acne[29] (table I). The study was designed specifically to assess
the effect of treatment on acne; clinical response was defined as
at least a 50% reduction from baseline in the number of pap-
ules/pustules on the face. After six treatment cycles, the median
reduction from baseline in the number of papules and/or pus-
tules on the face was greater in women receiving EE/CMA
(-63.6% vs -45.3%; p = 0.03) [figure 1].
The efficacy of EE/CMA in the treatment of acne was similar
to that of another low-dose oral contraceptive, ethinylestradiol/
levonorgestrel (EE/LNG) 0.03mg/0.15mg (Microgynon).[24]
In 199 women with mild-to-moderate papulopustular acne, a
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significantly greater proportion of women receiving EE/CMA ex-
perienced a clinical response (at least a 50% reduction from base-
line) after 12 treatment cycles (59.4% vs 45.9%; p= 0.02; table I).
The proportion of women with a complete response in pap-
ulopustular acne of the face after 12 cycles of treatment was also
greater in the EE/CMA group than the EE/LNG group (16.5% vs
4.3%; between-group significance was not reported). After 12
treatment cycles, papulopustular acne of the face, de´collete´ and
back were improved or resolved in women receiving EE/CMAand
EE/LNG (figure 2). Deterioration of acne was not observed in
women receiving EE/CMA, whereas very few patients receiving
EE/LNG experienced symptom deterioration.
A phase IV, open-label trial of EE/CMA in 44 women fur-
ther demonstrated the benefits of EE/CMA for the treatment of
acne-prone skin. After six menstrual cycles, women receiving
EE/CMA reported improvements in multiple skin parameters
including facial skin condition, the number of acne lesions and
pore size (table I).[41]
Skin condition (secondary endpoint) was improved in more
than 80% of women who had acne or other skin conditions in
two post-marketing surveillance trials investigating EE/CMA
in large patient populations (n = 21,820 and 2620; table I).[25,26]
Many other non-comparative and/or observational studies in-
vestigating the contraceptive efficacy of EE/CMA support data
from the previously mentioned well-designed trials.[34,36-40]
These clinical trials are summarized in table I.
7.2 Ethinylestradiol/Chlormadinone Acetate in Hirsutism
No clinical trials have been conducted to investigate the
efficacy of EE/CMA in hirsutism; however; several large phase
III trials that investigated the contraceptive effect of EE/CMA
and the efficacy of EE/CMA in women with acne also inves-
tigated the effects of EE/CMAon other signs of disorders of the
PSU (including hirsutism) as a secondary endpoint.[24,29,37]
Data from those studies have suggested a potentially favor-
able effect of EE/CMA on hirsutism in small subgroups
(n = 25–92).[24,29,37]
A greater proportion of patients with hirsutism at base-
line (n = 92) receiving EE/CMA demonstrated a total resolu-
tion of hirsutism symptoms compared with patients receiving
placebo in a multicenter, double-blind, placebo-controlled
study in 387 women with moderate papulopustular acne.[29]
Furthermore, in a single-blind study comparing the efficacy
of EE/CMA and EE/LNG in 199 women with mild-to-
moderate papulopustular acne, hirsutism disappeared com-
pletely in four out of 11 patients receiving EE/CMA. The
improvement observed in EE/CMA recipients was similar to
that of EE/LNG (five out of 14 patients).[24] None of the studies
mentioned in this section defined how hirsutism was diagnosed
and assessed, nor did they report the severity of hirsutism at
baseline.
The limited data from other studies also with small sub-
groups of patients with hirsutism suggest that EE/CMA treat-
ment for six to 12 cycles may improve this disorder; however,
further prospective large studies are required better to evaluate


























Fig. 1. Median number of papules and/or pustules of the face over six med-
ication cycles with ethinylestradiol/chlormadinone acetate (n= 251) or placebo
(n= 126). *p<0.05 vs placebo. (Adapted from Plewig et al.[29], with permission.)
Acne of décolleté 
(pap./pust.)


























































Fig. 2. Improvement, healing and deterioration rates for papulopustular
acne of the face, de´collete´ and back under ethinylestradiol/chlormadinone
acetate (EE/CMA) and ethinylestradiol/levonorgestrel (EE/LNG) after 12
treatment cycles.[24] Reproduced with permission from Worret et al.[24]
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7.3 Ethinylestradiol/Chlormadinone Acetate in
Female Pattern Hair Loss
Like hirsutism, there have been no clinical trials investigat-
ing the effects of EE/CMA in FPHL. However, a phase III
trial suggested that EE/CMA may be effective in this patient
population and worth investigation.[24] In the very small
number of patients who had FPHL (n = 18) in the large trial
(n = 199), resolution rates of 85.7% (six out of seven) and 90.9%
(10/11) were observed in the EE/CMA and EE/LNG groups,
respectively, following 12 cycles of treatment. The rating scale
to assess alopecia was not defined in the study and the severity
of alopecia at baseline was not reported. The efficacy of
EE/CMA in this condition cannot be concluded on this basis;
however, these limited data suggest that further investigation of
EE/CMA in FPHL is warranted.
7.4 Ethinylestradiol/Chlormadinone Acetate in Seborrhea
Several large clinical studies have indicated thatEE/CMAcould
possibly be a treatment for seborrhea; however, none of the trials
investigated EE/CMA in a seborrheic-specific population. In one
of the studies, seborrhea resolved in a large proportion of patients
receiving EE/CMA after 12 treatment cycles; this resolution was
similar to improvements observed in patients receiving EE/LNG
(table I).[24] The phase III, randomized controlled trial compared
the efficacy ofEE/CMAandEE/LNGin 199womenwithmild-to-
moderate papulopustular acne; 62of thesewomenhadmostlymild
or moderate seborrhea at baseline. Furthermore, in another phase
III trial, a greater proportion of patients with seborrhea at baseline
(n= 276) receiving EE/CMA demonstrated total symptom reso-
lution compared with patients receiving placebo (table I).[29]
Data from uncontrolled clinical trials investigating the
contraceptive efficacy of EE/CMA in women that support the
possible effect of EE/CMA in patients with seborrhea are pre-
sented in table I.[25,26,34,37,38,40]
Taken together, these limited data suggest that EE/CMA
may be effective for the management of seborrhea; however,
further examination of EE/CMA in seborrhea is required.
8. Tolerability
EE/CMA is generally well tolerated. The most commonly re-
ported adverse events in two post-marketing trials investigating
EE/CMA in large patient populations (n= 21820 and 2620) were
breast pain and headache/migraine (figure 3).[25,26] A small effect
of EE/CMA on average body weight was observed in those
studies, with an increase of 0.9–1.1% observed with EE/CMA
administration.[25,26] It is well known that oral contraceptives are
associated with a small increased risk of cardiovascular events. In
the two post-marketing trials, there was one case of thrombosis in
the thigh in the smaller trial, and in the larger study there was one
case each of superficial leg vein thrombosis and pulmonary em-
bolism, i.e., an incidence rate of 2.1 per 10 000 women years.
When administered for the treatment of acne, no unexpected
adverse events were experienced in women receiving EE/
CMA.[24,29] The toxicity profile was as expected; discontinua-
tions from study treatment occurred as a result of menstrual
bleeding, irritability and nausea.[29]
The tolerability profile of EE/CMA is broadly similar to
most low-dose combined oral contraceptives.[24,39] The most
common adverse events associated with these oral contra-
ceptives are weight gain, mood changes, loss of libido, mi-
graine, breast tenderness and intermenstrual bleeding.[1,29,37]
9. Conclusions
The dermatological conditions associated with hyper-
androgenemia are often a cause of major cosmetic concern in
women. EE/CMA is a combined monophasic contraceptive pill
with anti-androgenic properties that was better than placebo in
improving the symptoms of acne and similar to that of other low-
dose oral contraceptives in several large, well controlled studies in
patients with mild-to-moderate papulopustular acne. EE/CMA






















































Fig. 3. Incidences of themost common adverse events reported during the use
of ethinylestradiol/chlormadinone acetate (EE/CMA) 0.03mg/2mg. In two post-
marketing surveillance studies, 2620 (study 1)[25] and 21820 (study 2)[26] women
of reproductive age received 12 or six cycles of EE/CMA.[27] Reproduced with
permission from Curran and Wagstaff.[27]
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subgroups of women enrolled in several large trials investigating
the contraceptive efficacy of EE/CMA. EE/CMA is well tolerated
in clinical trials; adverse events reported with EE/CMA use were
those commonly reported with oral contraceptives. Evidence in
the literature indicates that the use of EE/CMA for the treatment
of dermatological disorders under the control of androgens may
be a valid treatment option. Further investigation is warranted.
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